WASHINGTON — The final two months before a presidential election don’t typically feature much policymaking, and there are rules about how quickly the government can implement big changes. But there’s a way for President Trump to pull off a major, last-minute policy change — and drug industry lobbyists are worried, given his campaign trail rhetoric on lowering drug prices, he just might.
The policy at issue, they say, is known as a “most favored nations” policy. It would drastically cut how much the U.S. pays for injectable drugs by tying reimbursement to lower prices paid in some other countries. The drug industry hates the idea, and says the policy would virtually decimate innovation.